|
Depreciation and amortization expense
|
|
$6.4m
|
$11.7m
|
$21.8m
|
$59.3m
|
$33.7m
|
$22.0m
|
$25.2m
|
|
Impairment loss
|
|
—
|
$0
|
$0
|
$210.1m
|
$10.4m
|
$0
|
$0
|
|
Net loss
|
|
($29.7m)
|
($192k)
|
($245.4m)
|
($549.0m)
|
($175.8m)
|
($52.3m)
|
($21.0m)
|
|
Stock-based compensation expense
|
|
$5.5m
|
$120.2m
|
$219.4m
|
$42.0m
|
($326k)
|
$9.1m
|
$32.2m
|
|
Change in fair value of financial liabilities
|
|
$0
|
$0
|
($198.4m)
|
($70.2m)
|
($1.2m)
|
$13.4m
|
$1.2m
|
|
Provision for excess and obsolete inventory
|
|
$0
|
$0
|
$2.1m
|
$1.1m
|
$3.9m
|
$180k
|
$135k
|
|
Legal reserves
|
|
—
|
—
|
—
|
—
|
$0
|
$0
|
$5.6m
|
|
Change in third party payor reserves
|
|
—
|
—
|
—
|
—
|
($9.7m)
|
$607k
|
$2.4m
|
|
Other
|
|
—
|
—
|
—
|
$2.7m
|
$2.4m
|
$3.6m
|
$3.2m
|
|
Accounts receivable
|
|
($4.6m)
|
($10.6m)
|
$5.5m
|
$5.5m
|
$10.3m
|
($5.4m)
|
($36.2m)
|
|
Inventory
|
|
($8.0m)
|
($9.0m)
|
($10.6m)
|
$2.4m
|
$975k
|
($2.6m)
|
($3.4m)
|
|
Accounts payable and accrued expenses
|
|
$12.8m
|
$14.8m
|
$25.9m
|
$34.5m
|
($47.0m)
|
($20.5m)
|
$12.1m
|
|
Other assets and liabilities
|
|
—
|
—
|
—
|
($8.5m)
|
($2.5m)
|
$3.7m
|
$12.0m
|
|
Purchases of marketable securities
|
|
—
|
—
|
—
|
$0
|
($47.7m)
|
($66.3m)
|
($55.7m)
|
|
Proceeds from sales of marketable securities
|
|
—
|
—
|
—
|
—
|
$0
|
$601k
|
$2.1m
|
|
Proceeds from maturities of marketable securities
|
|
—
|
—
|
—
|
$0
|
$17.8m
|
$41.1m
|
$44.0m
|
|
Purchases of property and equipment
|
|
($11.9m)
|
($24.1m)
|
($9.4m)
|
($7.2m)
|
($5.2m)
|
($5.5m)
|
($19.0m)
|
|
Proceeds from sales of assets
|
|
—
|
—
|
—
|
$0
|
$4.0m
|
$0
|
$0
|
|
Development of internal-use software assets
|
|
($3.5m)
|
($7.9m)
|
($11.4m)
|
($7.2m)
|
($461k)
|
$0
|
$0
|
|
Proceeds from offerings, net of issuance costs
|
|
—
|
$433.9m
|
—
|
$0
|
$143.0m
|
$46.5m
|
$46.7m
|
|
Proceeds from issuance of stock pursuant to employee stock purchase plan
|
|
—
|
—
|
—
|
—
|
$0
|
$497k
|
$3.0m
|
|
Exercise of stock options
|
|
$0
|
$0
|
$1.3m
|
$2.9m
|
$285k
|
$394k
|
$2.0m
|
|
Finance lease payoff and principal payments
|
|
—
|
($4.0m)
|
($3.7m)
|
($3.3m)
|
($3.6m)
|
($2.7m)
|
($2.5m)
|
|
Purchases of property and equipment in accounts payable and accrued expenses
|
|
$818k
|
$447k
|
$761k
|
$0
|
$134k
|
$2.6m
|
$6.3m
|
|
Stock consideration paid pursuant to exercise of Perceptive warrant
|
|
—
|
—
|
—
|
—
|
$0
|
$12.6m
|
$0
|
|
Assets acquired under capital leases obligations
|
|
—
|
$1.5m
|
$1.1m
|
$461k
|
$0
|
$689k
|
$0
|
|
Lease liability from obtaining right-of-use asset
|
|
—
|
—
|
—
|
$0
|
$637k
|
$0
|
$0
|
|
Net cash provided by (used in) operating activities
|
|
($18.7m)
|
($386k)
|
($190.4m)
|
($319.2m)
|
($180.1m)
|
($28.5m)
|
$33.3m
|
|
Acquisition of business, net of cash acquired and Consideration on escrow paid for Legacy GeneDx acquisition
|
|
—
|
$0
|
$0
|
($127.0m)
|
($12.1m)
|
$0
|
($32.9m)
|
|
Net cash used in investing activities
|
|
($15.5m)
|
($442.8m)
|
($20.8m)
|
($141.3m)
|
($43.7m)
|
($30.1m)
|
($61.5m)
|
|
Proceeds from long-term debt
|
|
$0
|
$15.9m
|
$0
|
$0
|
$48.5m
|
$0
|
$0
|
|
Long-term debt principal payments
|
|
$0
|
($186k)
|
($1.0m)
|
$0
|
($2.0m)
|
($497k)
|
($1.2m)
|
|
Issuance of common stock for first OPKO Milestone Payment
|
|
—
|
—
|
—
|
$0
|
$6.7m
|
$0
|
$0
|
|
Net cash provided by financing activities
|
|
$148.0m
|
$444.2m
|
$493.7m
|
$197.3m
|
$186.2m
|
$44.2m
|
$48.0m
|
|
Net increase (decrease) in cash, cash equivalents and restricted cash
|
|
$113.8m
|
$1.1m
|
$282.5m
|
($263.2m)
|
($37.6m)
|
($14.5m)
|
$19.8m
|
|
Cash, cash equivalents and restricted cash, at beginning of year
|
|
$115.0m
|
$119.0m
|
$401.5m
|
$138.3m
|
$100.7m
|
$86.2m
|
$106.0m
|
|
Cash paid for interest
|
|
$305k
|
$1.7m
|
$2.8m
|
$1.9m
|
$3.0m
|
$6.7m
|
$6.4m
|
|
Cash paid for taxes
|
|
$0
|
$0
|
$349k
|
$1.2m
|
$1.5m
|
$1.2m
|
$1.3m
|